Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis

Trial Profile

Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Expanded access
  • Sponsors Janssen-Cilag

Most Recent Events

  • 23 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 16 Jun 2014 Interim results (n=1078) of intention-to-treat analysis were published in the Journal of Hepatology.
  • 27 Dec 2012 Planned number of patients changed from 3000 to 3216 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top